Rare Unresectable or Metastatic BRAF V600E Mutation-positive Solid Tumors
1 clinical trials · Condition
◉ Watch Rare Unresectable or Metastatic BRAF V600E Mutation-positive Solid Tumors
| Record | Firm | Date |
|---|---|---|
| Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors (NCT05868629) | Novartis Pharmaceuticals | 2024-02-06 |
Track Rare Unresectable or Metastatic BRAF V600E Mutation-positive Solid Tumors automatically
Every clearance here is in the API, with alerts when new ones post.